Sequencing library construction methods and uses
By using amplification primers with a 5' G and ensuring 3' C ends for efficient A addition, the method improves sequencing library construction efficiency, reducing costs and complexity while enhancing detection capabilities.
Patent Information
- Application Number
- JP2024533124
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-01
- Filing Date
- 2022-11-18
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 2024541111000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This disclosure claims priority to Chinese Patent Application No. 2021114476422, entitled "Sequencing Library Construction Method and Use," filed on December 01, 2021, the contents of which are incorporated herein by reference in their entirety. The present disclosure relates to the field of sequencing technology, and in particular to sequencing library construction methods and uses. [Background technology]
[0002] High-throughput sequencing, also known as massively parallel sequencing or next-generation sequencing, can sequence multiple target regions of one sample or multiple samples at once, and its clinical use in pharmacogenomics, genetic disease research and screening, tumor mutation gene detection, clinical microbiological detection, etc. is gradually gaining attention.
[0003] Although whole genome sequencing has made great progress, there are still problems such as incomplete and inaccurate interpretation databases associated with this technology, and high sequencing costs. The high cost and technical complexity of this technology limit the use of whole genome sequencing. Therefore, various methods of high-throughput sequencing library construction for targeted region enrichment for specific genomic regions have been widely developed and used, thereby improving coverage and achieving the purpose of simplifying the process and reducing costs.
[0004] There are two main methods for library construction for target enrichment of specific regions: probe hybridization capture and multiplex PCR amplification. Among these, there are currently two main methods for library construction using multiplex PCR products: adding adapters to the products by ligation reaction, and adding adapters by two PCRs (the first one uses a primer with a universal sequence at the 5' end, and the second one adds adapters by annealing the primer). The library construction method of adding adapters to multiplex PCR products is the mainstream library construction method.
[0005] The ligation effect of TA sticky ends is superior to that of blunt ends, so the addition of adapters by TA ligation is now mostly used. Some DNA polymerases can catalyze the addition of A bases to the 3' ends of DNA fragments in a template-independent manner. This discovery laid the foundation for a series of techniques such as TA cloning and next-generation sequencing library construction. However, the current direct catalytic addition of A bases to the 3' ends of DNA fragments is inefficient and unstable. Summary of the Invention
[0006] Based on this, according to various embodiments of the present disclosure, an amplification primer for constructing a sequencing library is provided, comprising a primer sequence fragment complementary to a target fragment and a base G linked to the 5' end of the primer sequence fragment, wherein the amplification primer and the target fragment are not complementary at the base G.
[0007] In one embodiment, the base G is linked directly to the 5' end of the primer sequence fragment.
[0008] In one embodiment the base G is a base modified by phosphorylation.
[0009] According to various embodiments of the present disclosure, there is provided the use of the above amplification primers in the production of a kit for constructing a sequencing library.
[0010] According to various embodiments of the present disclosure, a method for constructing a sequencing library is provided, the method comprising: providing a primer sequence fragment used to carry out deoxyribonucleic acid amplification and library construction, the primer sequence fragment being complementary to a target fragment; The primer sequence fragment is subjected to a process to obtain an amplification primer having a base G at the 5' end, the process comprising: linking a base G to the 5' end of the primer sequence fragment when the base at the 5' end of the primer sequence fragment is not G, or linking or not linking a base G to the 5' end of the primer sequence fragment when the base at the 5' end of the primer sequence fragment is G; performing cyclic amplification on deoxyribonucleic acid using an amplification primer having a base G at its 5' end to obtain an amplified fragment having a base C at its 3' end; Adding the base A to the 3' end of the amplified fragment; and An adaptor containing a T sticky end is ligated to the amplified fragment with the base A added to the 3' end, and the adaptor contains the sequence required for the sequencing platform.
[0011] In one embodiment, the method further comprises phosphorylating the base G at the 5' end of the amplification primer prior to carrying out amplification of the deoxyribonucleic acid.
[0012] In one embodiment, the deoxyribonucleic acid is selected from the group consisting of sample DNA, a sample plasmid, and deoxyribonucleic acid obtained by reverse transcription of a sample RNA.
[0013] According to various embodiments of the present disclosure, there is provided a sequencing library constructed by the above-described method for constructing a sequencing library.
[0014] According to various embodiments of the present disclosure, a kit for constructing a sequencing library is provided, comprising the amplification primers described above.
[0015] In one embodiment, the kit further comprises at least one of a reagent for adding base A, a reagent for adding an adaptor, a reagent for PCR amplification, and a reagent for purification.
[0016] According to various embodiments of the present disclosure, there is provided a sequencing method comprising constructing a sequencing library of a sample using the above-described method for constructing a sequencing library and performing sequencing.
[0017] In one embodiment, the sequencing method is used to perform any one of mutation site detection, mutation site detection, gene fusion detection, and pathogenic microorganism detection on the sample.
[0018] In one embodiment, the mutation site comprises at least one of a bowel cancer mutation site, a cervical cancer mutation site, and a urothelial cancer mutation site.
[0019] In one embodiment, the chromosomal ploidy comprises at least one of a chromosomal ploidy of intestinal cancer, a chromosomal ploidy of cervical cancer, and a chromosomal ploidy of urothelial cancer.
[0020] In one embodiment, the gene fusion is an EML4-ALK gene fusion, a CD74-ROSI gene fusion, gene fusion, CCDC6-RET gene fusion, NCOA4-RET gene fusion, and / or TPM3-NTRK1 gene fusion.
[0021] In one embodiment, the pathogenic microorganism comprises at least one of influenza A virus, influenza B virus, and SARS-CoV-2.
[0022] In one embodiment, the sequencing is high-throughput sequencing.
[0023] According to various embodiments of the present disclosure, there is provided a mutation site detection kit comprising the above-described amplification primers.
[0024] According to various embodiments of the present disclosure, a chromosome ploidy detection kit is provided that includes the amplification primers described above.
[0025] According to various embodiments of the present disclosure, a gene fusion detection kit is provided that includes the amplification primers described above.
[0026] According to various embodiments of the present disclosure, a pathogenic microorganism detection kit is provided that includes the above-described amplification primers.
[0027] According to various embodiments of the present disclosure, there is provided a TA cloning method comprising the steps of performing PCR amplification using the amplification primers and adding A to the end of the amplification product.
[0028] The details of one or more embodiments of the disclosure are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the disclosure will become apparent from the description, the accompanying drawings, and the claims. [Brief description of the drawings]
[0029] To better describe and illustrate the embodiments and / or examples of the disclosure disclosed herein, reference may be made to one or more of the accompanying drawings, in which additional details or examples used to illustrate the accompanying drawings should not be construed as limiting the scope of the disclosed invention, any of the currently described embodiments and / or examples, and preferred aspects of the disclosure as currently understood. [Figure 1] FIG. 1 is a schematic diagram of a high-fidelity multi-enzyme DNA amplicon library construction process using conventional primers and primers of the present disclosure, according to one embodiment of the present disclosure. [Diagram 2] FIG. 2 is a schematic diagram of a DNA amplicon library construction process using conventional primers with non-high fidelity multiple enzymes and primers of the present disclosure, according to one embodiment of the present disclosure. [Diagram 3]FIG. 3 is a schematic diagram of a high-fidelity multi-enzyme RNA amplicon library construction process using conventional primers and primers of the present disclosure, according to one embodiment of the present disclosure. [Figure 4] FIG. 4 is a schematic diagram of an RNA amplicon library construction process using conventional primers with non-high-fidelity multi-enzymes and primers of the present disclosure, according to one embodiment of the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0030] To facilitate an understanding of the present disclosure, the present disclosure will now be described in more detail with reference to the accompanying drawings, in which various embodiments of the present disclosure are illustrated. However, the present disclosure may be embodied in many different forms and is not limited to the embodiments set forth herein. Rather, these embodiments are provided so that the present disclosure may be more thoroughly understood.
[0031] All technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure applies, unless otherwise defined. The terms used in the specification of this disclosure herein are for the purpose of describing particular embodiments only and are not intended to be limiting of the disclosure.
[0032] The addition efficiency of 3'-terminal dA varies depending on the template. For example, the addition efficiency of 3'-terminal dA depends on the nucleotide base composition at the 3'-end of DNA and varies between 4% and 75%. When the 3'-terminal nucleotide of DNA is base C, T, G, or A, the corresponding A addition efficiency is 80-85%, 75-80%, 45-50%, or 20-30%, respectively.
[0033] Therefore, the efficiency of A addition to DNA fragments with different ends is different.
[0034] In the present disclosure, by adding G to the 5' end of the forward primer and reverse primer (if the primer already has a G at its 5' end, no additional addition is necessary) so that the 3' ends of the top and bottom complementary strands of the amplicon are both C, the template-independent process of catalyzing the addition of A to the 3' end is guaranteed to have an equal probability of adding A to each strand, and the 3' end being C ensures a maximum efficiency of 80-85%, improving TA ligation efficiency.
[0035] This disclosure ensures higher A addition efficiency, allows more templates to be added with adapters by TA ligation, and improves library conversion rates. It also reduces processes such as end repair, and reduces the reduction in DNA recovery rate due to complex operations. This method is more useful for detecting low-frequency mutations.
[0036] In addition, in the application of TA cloning of PCR products, the cloning efficiency of this method is superior to that of conventional methods.
[0037] In a first aspect, an embodiment of the present disclosure provides an amplification primer for constructing a sequencing library, comprising a primer sequence fragment complementary to a target fragment and a base G linked to the 5' end of the primer sequence fragment, wherein the amplification primer and the target fragment are not complementary at the base G.
[0038] The term "complementary" as used herein means that two nucleic acid sequences can form hydrogen bonds with each other according to base pairing principles (Watson-Crick principles), thereby forming a duplex. In this disclosure, the term "complementary" includes "substantially complementary" and "fully complementary." The term "fully complementary" as used herein means that all bases of one nucleic acid sequence can pair with bases of another nucleic acid strand without the presence of mismatches or gaps. The term "substantially complementary" as used herein means that the majority of the bases of one nucleic acid sequence can pair with bases of the other nucleic acid strand, while allowing for the presence of mismatches or gaps (e.g., mismatches or gaps of one or more nucleotides). In general, under conditions that allow for hybridization, annealing, or amplification of nucleic acids, two nucleic acid sequences that are "complementary" (e.g., substantially complementary or fully complementary) selectively / specifically hybridize or anneal to form a duplex.
[0039] As used herein, the terms "target fragment," "target amplified fragment," and "target sequence" refer to The term refers to the target nucleic acid sequence to be amplified. In the present disclosure, the terms "target fragment", "target amplification fragment" and "target sequence" have the same meaning and can be used interchangeably. It is easily understood that the target fragment is specific to the sample sequence. In other words, under conditions that allow hybridization, annealing or amplification of nucleic acid, the amplification primer hybridizes or anneals only to a specific target fragment to amplify the specific fragment, and does not hybridize or anneal to other nucleic acid sequences.
[0040] If the amplification primer is complementary to a target fragment and the primer sequence segment is complementary to the target fragment, the amplification primer and the end of the target fragment are not complementary at the G base.
[0041] In some embodiments, the base G is linked directly to the 5' end of the complementary sequence, with no other intervening bases.
[0042] In some embodiments, the base G is a base modified by phosphorylation. The 5' end of the primer is modified by phosphorylation to ensure the phosphorylation state of the 5' end of the double-stranded product. Phosphorylation of the 5' end of the primer can reduce phosphorylation and purification steps in library construction, thus saving time and reducing molecular loss caused by multiple operation steps. The combination of adding G to the 5' end of the primer and phosphorylating the 5' end can improve library conversion rate and reduce loss rate.
[0043] In a second aspect, the present disclosure provides the use of the above amplification primer in the construction of a kit for constructing a sequencing library, which ensures that the kit achieves higher A addition efficiency, and allows more templates to be added with adapters by TA ligation, improving library conversion rate.The kit also reduces processes such as end repair, and reduces the decrease in DNA recovery rate caused by complex operations.
[0044] In a third aspect, embodiments of the present disclosure provide a method of constructing a sequencing library comprising: A primer sequence fragment for use in carrying out deoxyribonucleic acid amplification and library construction is provided, the primer sequence fragment being complementary to a target fragment, and comprising subjecting the primer sequence fragment to a process for obtaining an amplification primer having a base G at its 5' end, the process comprising: If the base at the 5' end of the primer sequence fragment is not G, linking the base G to the 5' end of the primer sequence fragment; or when the base at the 5' end of the primer sequence fragment is G, linking or not linking a base G to the 5' end of the primer sequence fragment; performing cyclic amplification on the deoxyribonucleic acid using an amplification primer to obtain an amplified fragment having a base C at the 3' end; adding the base A to the 3' end of the deoxyribonucleic acid; and An adapter containing a T sticky end is ligated to the amplified fragment with the base A added to the 3' end, and the adapter contains a sequence required for the sequencing platform.
[0045] Since the efficiency of 3'-end dA addition varies depending on the template, when the nucleotide base at the 3'-end is the base C, the corresponding A addition efficiency is highest. In the above-mentioned sequencing library construction method of the present disclosure, the base G (not necessary to be added if G is originally present) is added to the 5'-end of the PCR primer, so that the 3'-end of the PCR product becomes C, and it is ensured that the A addition efficiency of each product molecule is equal or higher. Since the efficiency of A addition to the end of the product is improved, the addition of adapters in TA ligation is improved. The ligation efficiency is improved in the reaction. Compared with conventional library construction methods, the method of obtaining an amplification product that contributes to A addition by introducing a modification to the primer end reduces the process of end repair after amplification, reduces the decrease in DNA recovery rate due to complicated operations, has a simple process, saves reagents, and has a high ligation efficiency to the adapter. This method can also be used for detection methods using sequencing, such as TA cloning of PCR products, detection of mutation sites, detection of chromosome ploidy, detection of gene fusion, and detection of pathogenic microorganisms.
[0046] The deoxyribonucleic acid is selected from the group consisting of a sample DNA, a sample plasmid, and a deoxyribonucleic acid obtained by reverse transcription of a sample RNA.
[0047] In some embodiments, the method of constructing a sequencing library further comprises amplifying the ligation products using adapter amplification primers to achieve pre-amplification of the library.
[0048] In a fourth aspect, embodiments of the present disclosure provide a sequencing library constructed by the method for constructing a sequencing library.
[0049] In a fifth aspect, embodiments of the present disclosure provide a kit for constructing a sequencing library.
[0050] A kit for constructing a sequencing library comprises the amplification primers of any of the above examples.
[0051] The term "kit" refers to any article (such as a package or container) that includes at least one device. The kit may further include any one of instructions, auxiliary reagents, components, or assemblies for use in the methods or steps thereof described herein.
[0052] Optionally, the kit also includes one or more of a reagent for adding A, a reagent for adding an adaptor, a reagent for PCR amplification, and a reagent for purification.
[0053] The reagents for adding A include an enzyme and dATP.
[0054] In some embodiments, the enzyme used to add A to the 3' end is any one or more selected from the group consisting of klenowex enzyme, Taq enzyme, and klenowex enzyme with Taq enzyme. Alternatively, the addition of A to the 3' end and the ligation of the adaptor are performed in one reaction system, or the addition of A to the 3' end is followed by purification and then ligation to the adaptor. Performing in one reaction system means that after A is added to the 3' end, the sequencing adaptor is directly ligated without purification. It is preferable to use Taq enzyme for the addition of A to the 3' end.
[0055] The reagent for adding the adaptor includes a ligase and an adaptor.
[0056] Ligases include HiFi Taq DNA Ligase, T4 RNA Ligase 2, Splint® Ligase, 9°N TMThe ligase is one or more selected from the group consisting of DNA ligase, Taq DNA ligase, T7 DNA ligase, T3 DNA ligase, electroligase, blunt end / TA ligase premix, instant sticky ligase premix, T4 DNA ligase, Circligase ssDNA ligase, and 5′ AppDNA / RNA thermostable ligase.
[0057] The adaptor has an overhanging T base at the 3' end and is used for complementary pairing with the sample DNA fragment after A is added.
[0058] The reagents used in the PCR amplification may be one or more selected from the group consisting of DNA polymerase, dNTPs, and a DNA polymerase buffer.
[0059] Further, the DNA polymerase may be selected from the group consisting of vent DNA polymerase, T7 DNA polymerase, Bsu DNA polymerase, T4 DNA polymerase, Klenow fragment, DNA polymerase I (E. coli), Therminator TM DNA polymerase, Sulfolobus DNA polymerase IV, phi29 DNA polymerase, Bst 2.0 DNA polymerase, Bst DNA polymerase, Deep VentR® DNA polymerase, Deep VentR TMand a combination of one or more enzymes selected from the group consisting of DNA polymerase, VentR® DNA polymerase, EpiMark® Hot Start Taq DNA polymerase, LongAmp® Hot Start Taq DNA polymerase, LongAmp® Taq DNA polymerase, Taq DNA polymerase large fragment, OneTaq® Hot Start DNA polymerase, Phusion® Hot Start Flex DNA polymerase, Phusion® Ultra-Fidelity DNA polymerase, and Q5® Hot Start Q5® ultra-fidelity DNA polymerase.
[0060] Additionally, the concentration of dNTPs may be 2.5 mM, 10 mM, etc. The DNA polymerase buffer is selected as the buffer that is most compatible with the selected polymerase.
[0061] The step of purifying the DNA fragment can be carried out by a conventional method in the art, for example, using magnetic beads for purification. Alternatively, the reagents used for purification include 1.8× magnetic beads, 0.9× magnetic beads, and EB solution.
[0062] In the kit of the present disclosure, the reagents are preferably packaged individually, but may be packaged together, provided that this does not affect the practice of the present disclosure.
[0063] In a sixth aspect, an embodiment of the present disclosure provides a sequencing method comprising constructing a sequencing library of a sample using the sequencing library construction method of the above embodiment and performing sequencing.
[0064] In the method of the present disclosure, the sample can be any sample to be sequenced.For example, in certain embodiments, the sample comprises or is DNA (e.g., genomic DNA or cDNA).In certain embodiments, the sample comprises or is RNA (e.g., mRNA).In certain embodiments, the sample comprises or is a mixture of nucleic acids (e.g., a mixture of DNA, a mixture of RNA, or a mixture of DNA and RNA).
[0065] In the method of the present disclosure, the sequence to be sequenced is not limited by its sequence composition or length.For example, the sequence to be sequenced can be DNA (e.g., genomic DNA or cDNA) or RNA molecule (e.g., mRNA).Furthermore, the target nucleic acid sequence to be detected can be single-stranded or double-stranded.
[0066] When the sample to be detected or the sequence to be sequenced is RNA, it is preferred to carry out reverse transcription before carrying out the method of the present invention to obtain the cDNA complementary to mRNA.For details of reverse transcription, see, for example, Joseph Sam-brook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2001).
[0067] The sample to be sequenced or the sequence to be sequenced may be obtained from any source, including, but not limited to, prokaryotic (such as bacteria), eukaryotic (such as protozoa, parasites, fungi, yeast, plants, animals including mammals and humans), or viruses (such as herpes viruses, HIV, influenza viruses, Epstein-Barr viruses, hepatitis viruses, polio viruses, etc.) or viroids. The sample to be sequenced or the sequence to be sequenced may be any form of nucleic acid sequence, such as a genomic sequence, an artificially isolated or fragmented sequence, or a synthetic sequence.
[0068] In some embodiments, the sample to be sequenced is blood, serum, plasma, cell culture supernatant, saliva, semen, tissue or tissue lysate.
[0069] The sequencing method in some embodiments of the present disclosure is high-throughput sequencing, also known as next-generation sequencing ("NGS"). Next-generation sequencing generates thousands to millions of sequences simultaneously in a parallel sequencing process. NGS is distinct from "Sanger sequencing" (first generation sequencing), the latter being based on electrophoretic separation of chain termination products in a single sequencing reaction. Sequencing platforms for NGS that may be used in the present disclosure may be commercially available, including but not limited to Illumina MiniSeq, NextSeq 550, life platform, etc.
[0070] The method can be used for non-diagnostic purposes, such as for studying genetics, racial distribution, human evolution and other areas (typically SNP applications).
[0071] In some embodiments, the sequencing methods of the above examples of the present disclosure can be used on samples for mutation site detection, chromosome ploidy detection, gene fusion detection, pathogenic microorganism detection, and other purposes.
[0072] In some embodiments, the mutation site comprises at least one of a colon cancer mutation site, a cervical cancer mutation site, and a urothelial cancer mutation site.
[0073] In some embodiments, the chromosomal ploidy comprises at least one of a chromosomal ploidy of intestinal cancer, a chromosomal ploidy of cervical cancer, and a chromosomal ploidy of urothelial cancer.
[0074] In some embodiments, the gene fusion comprises at least one of an EML4-ALK gene fusion, a CD74-ROSI gene fusion, a CCDC6-RET gene fusion, an NCOA4-RET gene fusion, and a TPM3-NTRK1 gene fusion.
[0075] In some embodiments, the pathogenic microorganism comprises at least one of influenza A virus, influenza B virus, and SARS-CoV-2.
[0076] In a seventh aspect, an embodiment of the present disclosure provides a mutation site detection kit comprising the amplification primers of any of the above embodiments.
[0077] In an eighth aspect, an embodiment of the present disclosure provides a chromosome ploidy detection kit comprising the amplification primers of any of the above embodiments.
[0078] In a ninth aspect, embodiments of the present disclosure provide a gene fusion detection kit comprising the amplification primers of any of the above embodiments.
[0079] In a tenth aspect, embodiments of the present disclosure provide a pathogenic microorganism detection kit comprising the amplification primers of any of the above embodiments.
[0080] In an eleventh aspect, there is provided a TA cloning method comprising the steps of performing PCR amplification using the amplification primers of any of the above Examples, thereby adding A to the end of the amplification product and improving the efficiency of adding A to the end of the PCR product. EXAMPLES
[0081] Example 1: Experimental procedures and methods (1) NGS-related experiments 1. Library construction from multiplex PCR products using conventional and disclosed methods.
[0082] The DNA library construction process is shown in FIG. 1 and FIG. Figure 1: A. When constructing libraries with high-fidelity enzymes using conventional methods, 5'-end phosphorylation and A addition of PCR products are performed after PCR reaction, with A addition efficiency at both ends being only 30%-37%, and then adapters are ligated. B. When constructing libraries with high-fidelity enzymes using the disclosed method, A is added directly to PCR products after PCR reaction, with A addition efficiency at both ends being 64%-72%, and then adapters are ligated.
[0083] Figure 2: A. When constructing a library with non-high fidelity enzymes using conventional methods, the PCR product undergoes A addition after the PCR reaction, with the A addition efficiency at both ends being only 30%-37%, and then the 5' end is phosphorylated and an adapter is ligated. B. When constructing a library with non-high fidelity enzymes using the disclosed method, after the PCR reaction, A is already added to the 3' end of the PCR product and phosphorylation occurs at the 5' end, with the A addition efficiency at both ends being 64%-72%, and an adapter can be directly ligated.
[0084] The RNA library construction process is shown in Figures 3 and 4. Figure 3: A. When constructing libraries with high fidelity enzymes using conventional methods, mRNA is reverse transcribed to cDNA before performing a PCR reaction, then the PCR products are 5'-end phosphorylated and A-added, with an A-addition efficiency of only 30%-37% at both ends, and then adapters are ligated. B. When constructing libraries with high fidelity enzymes using the disclosed method, mRNA is reverse transcribed to cDNA before performing a PCR reaction, then the PCR products are directly A-added, with an A-addition efficiency of 64%-72% at both ends, and then adapters are ligated.
[0085] Figure 4: A. When constructing a library with a non-high fidelity enzyme using conventional methods, mRNA is reverse transcribed to cDNA before PCR reaction, and A addition is already added to the 3' end of the PCR product after PCR reaction, with the A addition efficiency at both ends being only 30%-37%, and then the 5' end is phosphorylated and an adapter is ligated. B. When constructing a library with a non-high fidelity enzyme using the method of the present disclosure, mRNA is reverse transcribed to cDNA before PCR reaction, and A is already added to the 3' end of the PCR product after PCR reaction, and phosphorylation is performed at the 5' end, with the A addition efficiency at both ends being 64%-72%, and an adapter can be directly ligated.
[0086] 2. Detailed Experiments 1) Sample collection: Plasma samples: Whole blood was collected in EDTA blood collection tubes and centrifuged at room temperature for 1 hour to obtain plasma. Centrifugation conditions: Centrifuged at 1,500g for 10 minutes, the supernatant was aspirated and collected, and then centrifuged again at 15,000g for 10 minutes. The supernatant was aspirated and collected, which was the separated plasma.
[0087] Cervical exfoliated cell samples: Cervical exfoliated cell samples were collected in ThinPrep cervical exfoliated cell preservative, stored at 4°C, and centrifuged at 12,000 rpm for 10 min. The supernatant was discarded and the cervical exfoliated cell pellet was obtained.
[0088] Urine sample: Approximately 15–25 mL of morning urine was collected in a clean, dry disposable urine cup and centrifuged at 500 g for 10 min. The supernatant was discarded to obtain a urothelial cell pellet.
[0089] Colon cancer tissue sample: fresh colon cancer tissue preserved in RNAlater.
[0090] 2) Extraction of sample DNA and concentration measurement: Plasma DNA extraction: Plasma samples were extracted using the QIAAMP Circulating Nucleic Acid Kit (QIAGEN-55114).
[0091] Extraction of gDNA from exfoliated cervical cells: The CWBio Blood Genomic DNA Mini Kit (CW2087M) was used, and the starting volume of each sample was 2 mL.
[0092] Extraction of DNA from urine samples: DNA was extracted from urine samples using the CWBio Blood Genomic DNA Mini Kit (CW2087M).
[0093] Extraction of Colorectal Cancer FFPE Samples: PureLink TM DNA was extracted from colon cancer tissues using the Genomic DNA Mini Kit (Invitrogen).
[0094] DNA concentration was measured using Qubit.
[0095] 3) PCR target enrichment: High-fidelity and non-high-fidelity multiplex PCR enzymes were used for PCR, and the reaction system and conditions were in accordance with the instructions for the multiplex enzymes.
[0096] 4) Subsequent reactions: For details of reactions such as A addition, phosphorylation, and ligation, see each Example.
[0097] 5) Library concentration measurement and quality assessment: Library concentrations were measured by Qubit, and the reagent used was Qubit dsDNA HS Assay Kit, 500 assays (invitrogen / Q32854).
[0098] Library quality control: The validity of the libraries was assessed using the KAPA Library Quantification Kit Illumina® Platforms (KK4824).
[0099] 6) Library quality inspection: The resulting libraries were quality checked 2100 times using a high sensitivity DNA kit (Agilent / 5067-4626).
[0100] 7) On-machine sequencing of mixed samples: Sequencing was performed using the Illumina platform next500 or novaseq.
[0101] 8) Off-machine sequencing library analysis: The study data were analyzed for mutations and ploidy using Jiangsu Weizhen detection software and chromosomal abnormality analysis software, respectively, and pathogenic chromosomes were analyzed using Weizhen's in-house method.
[0102] (2) TA cloning-related experiments The zebrafish purg gene was PCR amplified and the product was subjected to TA cloning. The TA cloning efficiency of PCR products using conventional primers and various modified primers was investigated.
[0103] Zebrafish were purchased from Suzhou Mu Lei Biotechnology Co., Ltd. DNA extraction was performed by first homogenizing the cut tail fin with a tissue homogenizer, then extracting DNA using the DNeasy Blood & Tissue Kit (QIAGEN, Catalog No.: 69582), and measuring the DNA concentration with Qubit.
[0104] The kit used for the PCR reaction was Takara LA Taq DNA Polymerase (Takara Biotech). The amount of DNA template in the PCR reaction was 500 ng, and amplification was performed according to the PCR reaction system and conditions recommended in the instruction manual. The QIAquick PCR Purification Kit (QIAGEN) was used to purify and recover the PCR product. The 2100 was used to check whether the PCR fragments were the correct size and whether there were dimers. If there were dimers and nonspecific amplification, the GenElute TMGel cutting harvesting should be performed using a gel harvesting kit (Sigma-Aldrich). The concentration of the purified product was determined using Qubit.
[0105] The kit used for TA cloning was the Mighty TA-cloning Kit (Takara Biotech). The T vector and the PCR product to be inserted were mixed in a 1:3 molar ratio to a total volume of 5 μL. Then, 5 μL of Ligation Mighty Mix was added and mixed gently. The reaction was carried out at 16 °C for 30 min, and all was added to 100 μL of competent cells (E. coli, DH5α) for transformation. The cells were then spread on L agar plates containing X-Gal, IPTG, and Amp and grown overnight at 37 °C. The colonies were directly subjected to PCR to confirm recombinants.
[0106] Example 2: Library Effectiveness MRC-5 cell DNA was amplified using the four types of primers in Table 1, and the library efficiency of amplicon library construction using different primers was verified.
[0107] The primer sequences and modifications are shown in Table 17, including four types of primers, normal primer (1), primer (2) which is a normal primer with a phosphorylated 5' end, primer (3) which is a normal primer with a G added to the 5' end, and primer (4) which is a normal primer with a G added to the 5' end and phosphorylated, and the concentration of each primer in each type of primer pool was 400 nM. Multiplex PCR PCR reactions were performed using QIAGEN multi enzyme with the following system: add 10 μL of primer mixture, add 30 ng of template, add other components according to the instruction manual, and finally make up to 50 μL with water. The reaction conditions were set according to the instruction manual. The product was purified using a PCR product purification kit (QIAGEN) and eluted in 20 μL. For reactions such as base A addition, adapter ligation, and library preamplification, please refer to patent CN103298955B.
[0108] The effectiveness rate of libraries constructed with different primers was evaluated using Qubit dsDNA HS Assay kit, 500 assays (invitrogen / Q32854) and KAPA Library Quantification Kit Illumina® platform (KK4824). Actual effective concentration was the library concentration measured using KAPA Library Quantification Kit. Library effectiveness rate = actual effective concentration / library concentration (Qubit). See Table 1 for details.
[0109] [Table 1]
[0110] Results analysis: The library concentration and efficiency of the libraries constructed with four types of primers were normal. The library efficiency of primers with phosphorylated 5' end G was better than that of primers with phosphorylated 5' end G. The library efficiency of primers with phosphorylated 5' end G was better than that of primers with phosphorylated 5' end G. The library efficiency of primers with phosphorylated 5' end G was better than that of normal primers.
[0111] Example 3: Detection of sites in commercially available gDNA references Horizon positive reference HD734 and negative reference HD752 (100% wild type) were used to verify the detection efficiency of library construction using different primers.
[0112] The primer sequences and modifications are shown in Table 17, including four kinds of primers, normal primer (1), primer (2) which is a normal primer with a phosphorylated 5' end, primer (3) which is a normal primer with a G added to the 5' end, and primer (4) which is a normal primer with a G added to the 5' end and phosphorylated, and the concentration of each primer in each kind of primer pool was 400 nM. A multiplex PCR reaction was performed in a PCR reaction system using a kit (Phusion U Multiplex PCR Master Mix, Thermo Scientific) as follows: add 10 μL of primer mixture, add 30 ng of template, add other components according to the instruction manual, and finally make up to 50 μL with water. The reaction conditions were set according to the instruction manual. The product was purified using a PCR product purification kit (QIAGEN) and eluted in 20 μL. The product obtained using the first primer needed to be phosphorylated. T4 PNK enzyme from NEB was used, and the reaction system and conditions were set according to the enzyme's instruction manual. The product was purified with a QIAGEN kit. Refer to patent CN103298955B. The experiment was repeated 10 times. The detection results are shown in Table 2.
[0113] [Table 2]
[0114] Results analysis: For wild-type reference, none of the sites were detected using the four primers. For sites with high mutation frequency (AF≧8%), all four primers were able to detect the sites with 10 detections. For sites with low mutation frequency (1%≦MAF≦1.5%), ), the detection rate for the four low-frequency sites was 52.5% for normal primers, 65% for primers with phosphorylated 5' ends, 82.5% for primers with G added to the 5' ends, and 97.5% for primers with G added and phosphorylated 5' ends. The results showed that adding G to the 5' end was more effective for low-frequency detection compared to phosphorylation. The effect was even better when phosphorylation was performed in addition to adding G.
[0115] Example 4: Detection of sites in commercially available cfDNA references Horizon positive reference HD813 and negative reference HD815 (100% wild type) were used to verify the detection efficiency of library construction using different primers.
[0116] The primer sequences and modifications are shown in Table 17, including four types of primers, normal primer (1), primer (2) which is a normal primer with a phosphorylated 5' end, primer (3) which is a normal primer with a G added to the 5' end, and primer (4) which is a normal primer with a G added to the 5' end and phosphorylated, and the concentration of each primer in each type of primer pool was 400 nM. A PCR reaction system multiplex PCR reaction was performed using a kit (Phusion U Multiplex PCR Master Mix, Thermo Scientific) as follows: Add 10 μL of primer mixture, add 30 ng of template, add other components according to the instruction manual, and finally make up to 50 μL with water. The reaction conditions were set according to the instruction manual. The product was purified using a PCR product purification kit (QIAGEN) and eluted in 20 μL. The product obtained using the first primer needed to be phosphorylated. NEB's T4 PNK enzyme was used, and the reaction system and conditions were set according to the enzyme's instruction manual. The product was purified with a QIAGEN kit. Refer to patent CN103298955B. The experiment was repeated 10 times. The detection results are shown in Table 3.
[0117] [Table 3]
[0118] Results analysis: When detecting the wild-type reference, none of the sites were detected using the four types of primers. At sites with 1%≦MAF≦1.5%, the detection rate of the normal primer was 53.8%, the detection rate of the primer with phosphorylated 5' end was 63.8%, the detection rate of the primer with G added to the 5' end was 81.3%, and the detection rate of the primer with G added and phosphorylated 5' end was 97.5%. Comparing primers 1 and 2, it can be seen that phosphorylation of the 5' end is beneficial for detecting low-frequency sites. Comparing primers 2 and 3, it can be seen that adding G to the 5' end is beneficial for detecting low-frequency sites. Overall, the combination of adding G to the 5' end and phosphorylation was effective for detecting low-frequency mutations.
[0119] Example 5: Site detection of homemade reference gDNA A reference A containing multiple mutation sites was prepared by blending multiple cell lines. The mutation frequency of each site is shown in Table 2. The four primers in Example 2 were used for detection. The multiplex PCR method was the same as in Example 2. The product obtained using the first primer was phosphorylated using the T4 PNK kit from Invitrogen, and then purified using a QIAGEN kit. Base A addition, adapter ligation, and library preamplification For such reactions, please refer to Patent CN108251515A. The experiment was repeated 10 times. The detection results are shown in Table 4.
[0120] Results analysis: When detecting the wild-type reference, none of the sites were detected using the four types of primers. At sites with 2%≦MAF≦5%, the detection rate of the normal primer was 85%, the detection rate of the 5'-terminal phosphorylated primer was 88.3%, the detection rate of the primer with G added to the 5'-end was 90%, and the detection rate of the primer with G added and phosphorylated at the 5'-end was 100%. At sites with 0.5%≦MAF≦1%, the detection rate of the normal primer was 58.6%, the detection rate of the 5'-terminal phosphorylated primer was 71.4%, the detection rate of the primer with G added to the 5'-end was 82.1%, and the detection rate of primer 4 was 93.6%. Overall, the combination of adding G to the 5'-end and phosphorylation was effective in detecting low-frequency mutations.
[0121] [Table 4]
[0122] Example 6: Site detection of self-made reference cfDNA The extracted cell line DNA was sonicated to fragment to about 170bp. After passing the 2100 quality inspection, multiple cell lines were blended to prepare Reference B containing multiple mutation sites. The mutation frequency of each site is shown in Table 2. The four types of primers in Example 2 were used for detection. The multiplex PCR method was the same as in Example 2. The product obtained using the first primer was phosphorylated using Invitrogen's T4 PNK kit, and then purified using a QIAGEN kit. For reactions such as base A addition, adapter ligation, and library pre-amplification, please refer to patent CN108251515A. The experiment was repeated 10 times. The detection results are shown in Table 5.
[0123] Results analysis: When detecting the wild-type reference, none of the sites were detected using the four primers. At sites with 2%≦MAF≦5%, the detection rate of primer 1 was 52 / 60=86.7%, primer 2 was 56 / 60=93.3%, primer 3 was 95%, and primer 4 was 98.33%. At sites with 0.5%≦MAF≦1%, the detection rate of primer 1 was 49.3%, primer 2 was 57.1%, primer 3 was 70%, and primer 4 was 84.3%. Comprehensive comparison, primer 4 (combining the addition of G to the 5' end and phosphorylation) is more advantageous for detecting low-frequency mutations.
[0124] [Table 5]
[0125] Example 7: Detection of sites in nucleosomes Nucleosomes were prepared using EpiScope® Nucleosome Preparation Kit (Takara Code No. 5333). Nucleosomes prepared from multiple cell lines were blended to prepare Reference C, which contains multiple mutation sites. The mutation frequency of each site is shown in Table 2. The four types of primers in Example 2 were used for detection. The multiplex PCR method was the same as in Example 2. The product obtained using the first primer was phosphorylated using Invitrogen's T4 PNK kit, and then purified using a QIAGEN kit. For reactions such as base A addition, adapter ligation, and library preamplification, please refer to patent CN108251515A. The experiment was repeated 10 times. The detection results are shown in Table 6.
[0126] Results analysis: When detecting the wild-type reference, none of the sites were detected using the four primers. For sites with 2%≦MAF≦5%, the detection rate of primer 1 was 86.7%, the detection rate of primer 2 was 93.3%, the detection rate of primer 3 was 95%, and the detection rate of primer 4 was 96.7%. The detection rate of primer 4 was 98.3%. At sites with 0.5%≦MAF≦1%, the detection rate of primer 1 was 50.7%, that of primer 2 was 62.1%, that of primer 3 was 75%, and that of primer 4 was 86.4%. Comprehensively, primer 4 (combining the addition of G to the 5' end and phosphorylation) is more advantageous for detecting low-frequency mutations.
[0127] [Table 6]
[0128] Example 8: Site detection in colon cancer plasma samples Plasma samples from 21 intestinal cancer patients and 10 healthy subjects were collected. DNA was extracted and multiplex PCR was performed using the four primers in Table 17. Multiplex PCR amplification was performed using Vazyme multiplex enzyme, and the PCR products were subjected to experiments such as base A addition, adapter ligation, and library pre-amplification using the KAPA library construction kit. The detection results are shown in Table 7.
[0129] [Table 7] TIFF2024541111000009.tif20151
[0130] In the detection using four types of primers, all healthy subjects were negative. In the detection of CRC, when an amplicon library was constructed using normal primers, detection was achieved in eight samples (all single site detection), with a detection rate of 38.1%. When a primer with G added to the 5' end was used, it was detected in 9 samples (all single site detection), with a detection rate of 42.9%. When a primer with G added to the 5' end was used, it was detected in 15 samples (double site detection in 2 samples), with a detection rate of 71.4%. When a primer with G added to the 5' end and phosphorylated was used, it was detected in 16 samples (double site detection in 6 samples), with a detection rate of 76.2%. It was found that adding G to the 5' end of the primer significantly improved the detection rate. When G was added in combination with phosphorylation, detection became more stable.
[0131] Example 9: Detection of sites in cervical exfoliated cell samples Cervical exfoliated cell samples were collected, including 15 cases of cervical cancer with clear pathological information, 5 cases of CIN3, 5 cases of CIN2, and 5 cases of CIN1, and multiplex PCR was performed on these 30 samples using the four primers in Table 17. Multiplex PCR amplification was performed using Vazyme multiplex enzyme, and the PCR products were subjected to experiments such as base A addition, adapter ligation, and library pre-amplification using the NEB library construction kit. The detection results are shown in Table 8.
[0132] [Table 8] TIFF2024541111000011.tif114161
[0133] In the libraries of cervical cancer samples, the detection rate of primer 1 was 9 / 15=60%, and the detection rate of cervical cancer when the library was constructed with primer 2 was 10 / 15=66.7%. The detection rate of primer 3 was 13 / 15=86.7%, and the detection rate of cervical cancer when the library was constructed with primer 4 was 15 / 15=100%. In CIN3, the detection rate of primer 1 was 0 / 5=0%, the detection rate of primer 2 was 2 / 5=40%, the detection rate of primer 3 was 3 / 5=60%, and the detection rate of primer 4 was 4 / 5=80%. In CIN2, the detection rate of primer 1 was 0 / 5=0%, the detection rate of primer 2 was 1 / 5=20%. The detection rate of the library constructed with primer 3 was 2 / 5=40%, and the detection rate of primer 4 was 3 / 5=60%. No sites were detected in CIN1 samples using libraries constructed with four types of primers. Primer 4 (combining the addition of G to the 5' end and phosphorylation) was able to detect more chromosomal abnormalities.
[0134] Example 10: Detection of sites in urine samples Twenty urine samples from urothelial cancer patients and 10 urine samples from healthy individuals were collected. DNA was extracted and multiplex PCR was performed using four types of primers. Thermo Fisher reagents were used for multiplex PCR, and the PCR products were subjected to experiments such as base A addition, adapter ligation, and library amplification using the Vazyme library construction kit. The detection results are shown in Table 9.
[0135] [Table 9] TIFF2024541111000013.tif158153
[0136] All healthy subjects were negative. In the detection of urothelial cancer samples, the detection rate was 7 / 20=35% when the amplicon library was constructed using normal primers, 10 / 20=50% when the amplicon library was constructed using primers with phosphorylated 5' ends, 13 / 20=65% when the amplicon library was constructed using primers with G added to the 5' end, and 16 / 20=80% when the amplicon library was constructed using primers with G added to the 5' end and phosphorylated. These showed the best detection effect.
[0137] Example 11: Ploidy detection limit The positive cell line reference Hela cells with 6 copies of chromosome 5 confirmed by FISH were mixed with the negative cell line with 2 copies in different ratios to obtain different copy number references. For details, please refer to Table 10. Four kinds of primers in Table 18 were used for amplification, respectively, and Thermo Fisher's multiplex high fidelity enzyme was used for amplification. For the experiments of amplicon base A addition, adapter ligation, and library preamplification, please refer to patent CN103298955B. The detection results are shown in Table 10.
[0138] [Table 10]
[0139] As a result of the duplex test, amplification with normal primers showed a minimum detection limit of 2.8 copies, and ploidy could be stably detected. The minimum detection limit for primers with phosphorylated 5' ends was 2.4 copies. The minimum detection limit for amplification with primers with G added to the 5' ends was 2.2 copies. The minimum detection limit for amplification with primers with G added and phosphorylated 5' ends was 2.04 copies, showing the best detection effect ( TIFF2024541111000015.tif10146 indicates that chromosome 5 was detected as positive, and × indicates that chromosome 5 was not detected).
[0140] Example 12: Detection of polyploidy in colon cancer FFPE samples Twenty FFPE samples of intestinal cancer with clear pathological information were collected. Amplification was performed using the four primers in Table 18. KAPA high fidelity enzyme was used for PCR, and the products were subjected to base A addition, adapter ligation, and library preamplification experiments using the KAPA library construction kit. Chromosomal abnormalities were examined. The results are shown in Table 11.
[0141] [Table 11] TIFF2024541111000017.tif55168
[0142] In the detection of intestinal cancer FFPE samples, the detection rate of chromosomal ploidy changes when amplicon libraries were constructed using primer 1 was 11 / 25 = 44%, the detection rate of chromosomal ploidy changes when amplicon libraries were constructed using primer 2 was 14 / 25 = 56%, the detection rate of chromosomal ploidy changes when amplicon libraries were constructed using primer 3 was 17 / 25 = 68%, and the detection rate of chromosomal ploidy changes when amplicon libraries were constructed using primer 4 was 22 / 25 = 88%, indicating that more chromosomal abnormalities were detected when amplicon libraries were constructed using primer 4.
[0143] Example 13 Detection of polyploidy in exfoliated cervical cell samples Cervical exfoliated cell samples with clear pathological information were collected. 15 cases of cervical cancer, 5 cases of CIN3, 5 cases of CIN2, and 5 cases of CIN1. These 30 samples were subjected to different methods to construct polyploidy libraries. Four kinds of primers in sequence table 2 were used. Amplification was performed by QIAGEN multiplex enzyme (no need to add A to the product), and KAPA library construction kit was used for adapter ligation and library pre-amplification. The detection results are shown in Table 12.
[0144] [Table 12] TIFF2024541111000019.tif90168
[0145] Results analysis: In the libraries of cervical cancer samples, the detection rate of primer 1 was 8 / 15=53.5%, and the detection rate of cervical cancer was 10 / 15=66.7% when the amplicon library was constructed using primer 2. The detection rate of primer 3 was 13 / 15=86.7%, and the detection rate of cervical cancer was 15 / 15=100% when the amplicon library was constructed using primer 4. In CIN3, the detection rate of primer 1 was 0 / 5=0%, the detection rate of primer 2 was 2 / 5=40%, the detection rate of primer 3 was 3 / 5=60%, and the detection rate of primer 4 was 4 / 5=80%.
[0146] In CIN2, the detection rate of primer 1 was 0 / 5=0%, that of primer 2 was 1 / 5=20%, that of the library constructed with primer 3 was 2 / 5=40%, and that of primer 4 was 3 / 5=60%. No sites were detected in the CIN1 sample using the library constructed with four primers. Primer 4 (combining phosphorylation with the addition of G at the 5' end) was able to detect more chromosomal abnormalities.
[0147] Example 14 Detection of polyploidy in urothelial carcinoma samples Twenty urothelial carcinoma samples with clear pathological information were collected and subjected to different methods to construct polyploid libraries. Four kinds of primers in Table 18 were used. PCR enzyme used was KAPA multiplex enzyme (no need to add A to the product), and NEB library construction kit was used for adapter ligation and library preamplification. The detection results are shown in Table 13.
[0148] [Table 13] TIFF2024541111000021.tif44167
[0149] Results analysis: In the libraries of urothelial carcinoma samples, the detection rate of chromosomal ploidy changes was 14 / 25=56% when amplicon library construction was performed using primer 1. The detection rate of chromosomal ploidy changes was 18 / 25=72% when amplicon library construction was performed using primer 2. The detection rate of chromosomal ploidy changes was 21 / 25=84% when amplicon library construction was performed using primer 3. The detection rate of chromosomal ploidy changes was 23 / 25=92% when amplicon library construction was performed using primer 4. More chromosomal abnormalities may be detected by amplicon library construction using primer 4.
[0150] Example 15: RNA Fusion Detection RNA Fusion Reference: Seraseq® Fusion RNA Mix v4 was mixed in different volumes with genetic background confirmed wild type (fusion negative) cell line GM12878 RNA at a concentration of 25 ng / μL to investigate the lower limit of detection of library construction methods using the four different modified primers in Table 19. The RNA was analyzed using SuperScript TM VILO TM A cDNA synthesis kit was used for reverse transcription, and a QIAGEN kit was used for cDNA purification. QIAGEN multiplex enzyme was used for multiplex PCR (no need to add A to the product), and Vazyme library construction kit was used for adapter ligation and library pre-amplification. Each fusion type was detected 10 times with different mixing ratios. The detection results are shown in Table 14.
[0151] [Table 14]
[0152] Results analysis: Five fusion types were detected. When the mixture concentration was 0%, virtually no detection was observed by both methods. When the mixture concentration was 10%, the cumulative detection rate of primer 1 was 94%. The cumulative detection rate of primer 2 was 97.3%, the cumulative detection rate of primer 3 was 98.7%, and the cumulative detection rate of primer 4 was 100%. When the mixture concentration was 5%, the cumulative detection rate of primer 1 was 87.3%, the cumulative detection rate of primer 2 was 91.3%, the cumulative detection rate of primer 3 was 95.3%, and the cumulative detection rate of primer 4 was 100%. When the mixture concentration was 2.5%, the cumulative detection rate of primer 1 was 61.3%, the cumulative detection rate of primer 2 was 67.3%, the cumulative detection rate of primer 3 was 78.7%, and the cumulative detection rate of primer 4 was 92%. At a mixed concentration of 1.25%, the cumulative detection rate of primer 1 was 42.7%, that of primer 2 was 52.6%, that of primer 3 was 67.3%, and that of primer 4 was 81.3%. These results showed that primer 4 was more effective than primer 1 in detecting low-frequency fusions.
[0153] Example 16 Detection of pathogenic microorganisms The amplicon regions to be detected were integrated into the same plasmid containing a T7 promoter, and RNA references were obtained after in vitro transcription. The size and concentration of the target fragments were detected at 2100 and then converted to copy number concentrations. The different copy number references were used to evaluate the amplicon detection ability of different modified primers. Reverse transcription was performed using SuperScript IV reverse transcriptase, and a QIAGEN kit was used for cDNA purification. Multiplex PCR was performed with the four types of primers in Table 20, respectively, KAPA multiplex enzyme was used for multiplex PCR (no need to add A to the product), and NEB library construction kit was used for adapter ligation and library preamplification. Ten detections were performed with different copy numbers. The detection results are shown in Table 15.
[0154] [Table 15]
[0155] Results analysis: The detection ability (reverse transcription reaction) of three pathogenic microorganisms with different copy numbers was examined. When the copy number was 10, detection was possible in all 10 tests. When the copy number was 5, the detection rate of primer 1 was 93.3%, the detection rate of primer 2 was 96.7%, the detection rate of primer 3 was 96.7%, and the detection rate of primer 4 was 100%. When the copy number was 2.5, the detection rate of primer 1 was 66.7%, the detection rate of primer 2 was 76.7%, and the detection rate of primer 3 was 100%. The detection rate of primer 3 was 86.7%, and the detection rate of primer 4 was 96.7%. For copy number 0, two primers were negative. Primer 4 showed a better effect than primer 1 in detecting low-concentration pathogenic microorganisms.
[0156] Example 17: Comparison of TA cloning efficiency of PCR products using different primers The promoter region of zebrafish purg gene was amplified using primers synthesized by different methods as shown in Table 21. Three TA clones were tested in parallel for each type of primer. PCR products were TA cloned according to the method of Example 1. The white spot number (insertion confirmation) and cloning efficiency (white spot rate) are detailed in Table 16 below.
[0157] [Table 16]
[0158] Results analysis: Regular primers had the worst effect on the number of white spots and cloning efficiency, while primers phosphorylated with G at the 5' end had the best effect. Since all other control conditions in the experiment (transfection, plating, culture conditions, etc.) were the same and the only variable was the different primers, the products using primers phosphorylated with G at the 5' end showed higher TA ligation efficiency.
[0159] Specifically, the primers used in each example are as follows: [Table 17] TIFF2024541111000026.tif218151TIFF2024541111000027.tif219151TIFF2024541111000028.tif215151TIFF2024541111000029.tif114152
[0160] [Table 18] NOTE: N represents random primers.
[0161] [Table 19] TIFF2024541111000032.tif219151TIFF2024541111000033.tif218153TIFF2024541111000034.tif219153TIFF2024541111000035.tif153151
[0162] [Table 20] TIFF2024541111000037.tif221155TIFF2024541111000038.tif93151
[0163] [Table 21]
[0164] Each of the technical features of the above-mentioned embodiments can be combined in any combination. For the sake of simplicity, we have not described all possible combinations of each of the technical features of the above-mentioned embodiments. However, all combinations of these technical features should be considered within the scope of the present disclosure, unless such combinations are mutually inconsistent.
[0165] The above examples merely illustrate some embodiments of the present disclosure to facilitate a specific and detailed understanding of the technical solutions of the present disclosure, and do not limit the scope of protection of the present disclosure. It should be noted that a number of variations and modifications may be made by those skilled in the art without departing from the concept of the present disclosure, and all of them are within the scope of protection of the present disclosure. Therefore, the scope of protection of the present disclosure is based on the appended claims, and the specification can use the description to interpret the content of the claims.
Claims
1. An amplification primer for constructing a sequencing library, comprising a primer sequence fragment complementary to a target fragment and a base G linked to the 5' end of the primer sequence fragment, wherein the amplification primer and the target fragment are not complementary at the base G.
2. 2. The amplification primer of claim 1, wherein the base G is linked directly to the 5' end of the primer sequence fragment.
3. 3. The amplification primer of claim 1, wherein the base G is a base modified by phosphorylation.
4. 4. Use of an amplification primer according to any one of claims 1 to 3 in the preparation of a kit for constructing a sequencing library.
5. 1. A method for constructing a sequencing library, comprising: providing a primer sequence fragment used to carry out deoxyribonucleic acid amplification and library construction, said primer sequence fragment being complementary to a target fragment; treating said primer sequence fragment to obtain an amplification primer having a G base at its 5' end; Here, the process is linking a base G to the 5' end of the primer sequence fragment if the base at the 5' end of the primer sequence fragment is not G, or linking or not linking a base G to the 5' end of the primer sequence fragment if the base at the 5' end of the primer sequence fragment is G; performing cyclic amplification on the deoxyribonucleic acid using the amplification primer to obtain an amplified fragment having a base C at the 3' end; adding a base A to the 3' end of the amplified fragment; and Ligating an adaptor containing a T sticky end to the amplified fragment having a base A added to the 3' end, the adaptor containing a sequence required for a sequencing platform; The method includes:
6. The method for constructing a sequencing library according to claim 5, further comprising phosphorylating the base G at the 5' end of the amplification primer prior to amplifying the deoxyribonucleic acid.
7. The method for constructing a sequencing library according to claim 5 or claim 6, wherein the deoxyribonucleic acid is selected from the group consisting of sample DNA, sample plasmid, and deoxyribonucleic acid obtained by reverse transcription of sample RNA.
8. A sequencing library constructed by the method for constructing a sequencing library according to any one of claims 5 to 7.
9. A kit for constructing a sequencing library, comprising the amplification primer according to any one of claims 1 to 3.
10. 10. The kit of claim 9, further comprising at least one of a reagent for adding base A, a reagent for adding an adaptor, a reagent for PCR amplification, and a reagent for purification.
11. A method for constructing a sequencing library according to any one of claims 5 to 7. and constructing a sequencing library of the sample using the method.
12. The sequencing method of claim 11, which is used to perform any one of mutation site detection, chromosomal ploidy detection, gene fusion detection, and pathogenic microorganism detection on the sample.
13. 13. The sequencing method of claim 12, wherein the mutation site detection includes at least one of a colon cancer mutation site, a cervical cancer mutation site, and a urothelial cancer mutation site.
14. 13. The method of claim 12, wherein the chromosomal ploidy comprises at least one of a chromosomal ploidy of intestinal cancer, a chromosomal ploidy of cervical cancer, and a chromosomal ploidy of urothelial cancer.
15. 13. The sequencing method of claim 12, wherein the gene fusion comprises at least one of an EML4-ALK gene fusion, a CD74-ROSI gene fusion, a CCDC6-RET gene fusion, an NCOA4-RET gene fusion, and a TPM3-NTRK1 gene fusion.
16. 13. The sequencing method of claim 12, wherein the pathogenic microorganism comprises at least one of influenza A virus, influenza B virus, and SARS-CoV-2.
17. 17. The sequencing method of claim 11, wherein the sequencing is high-throughput sequencing.
18. A mutation site detection kit comprising the amplification primer according to any one of claims 1 to 3.
19. A chromosome ploidy detection kit comprising the amplification primer according to any one of claims 1 to 3.
20. A gene fusion detection kit comprising the amplification primer according to any one of claims 1 to 3.
21. A pathogenic microorganism detection kit comprising the amplification primer according to any one of claims 1 to 3.
22. A TA cloning method comprising the steps of performing PCR amplification using the amplification primer according to any one of claims 1 to 3 and adding A to the end of the amplified product.
Citation Information
Patent Citations
Sequence modification of oligonucleotide primers to manipulate non-templated nucleotide addition
EP0857220A1
Biomarkers for theranosis
JP2013521502A
Thermostable cellobiohydrolase
JP2017175958A
Next-generation sequencing libraries
US20150051116A1
Cited By
Method for preparing multiplex PCR amplification libraries based on single-ended sequencing and its application
JP2026134697A
